Affiliation:
1. City Clinical Hospital No. 33
2. City Clinical Hospital No. 33; Lobachevsky State University of Nizhny Novgorod; ”Medical Centre MEDIS” LLC, Nizhny Novgorod
3. ”Medical Centre MEDIS” LLC, Nizhny Novgorod
Abstract
In multiple sclerosis (MS), the development and introduction of disease-modifying treatments (DMTs) into clinical practice can improve treatment outcomes. Interferon beta drugs are commonly used as DMTs. Among these drugs, sampeginterferon beta-1a (Tenexia®) was recently approved – an innovative original development of BIOCAD that is the next pegylated interferon beta-1a in its class. Clinical observations of patients with relapsing-remitting MS who received Tenexia® are presented. In the first clinical observation, the patient initially received glatiramer acetate as DMT, which led to exacerbations and an increase in neurological disturbances. The patient was switched to treatment with Tenexia®, during which no exacerbations and no increase in neurological disturbances were observed. In the second observation, the patient, who had been suffering from MS for 11 years, did not receive any DMTs. A year ago, the drug Tenexia® was prescribed as a DMT for the first time, with no exacerbations, no increase in neurological disturbances or negative changes on MRI during treatment. In the third observation, a patient suffering from MS for 5 years was initially prescribed teriflunomide as DMT, with exacerbations and an increase in neurological disturbances noted during the treatment. The patient was switched to Tenexia®, which led to a stable remission. The presented observations reflect the positive experience with the use of the drug sampeginterferon beta-1a in real-life clinical practice.
Reference12 articles.
1. Pegylated interferon in Russian clinical practice. Focus on effective therapy for moderately active multiple sclerosis. International Congress “Multiple Sclerosis and Other Neuroimmunological Diseases – 2022”. Effektivnaya farmakoterapiya = Effective pharmacotherapy. 2022;18(26):48-52 (In Russ.)].
2. Boyko AN, Bakhtiyarova KZ, Dudin VA, et al. New pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10-2):100-10. doi: 10.17116/jnevro2019119102100 (In Russ.).
3. Boyko AN, Boyko OV, Bakhtiyarova KZ, et al. Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1):62-71. doi: 10.17116/jnevro202212201162 (In Russ.).
4. General characteristics of the medicinal prodinal products of the EAEU. Available at: https://lk.regmed.ru/Register/EAEU_SmPC (accessed 13.06.2024) (In Russ.).
5. Boyko AN, Bakhtiyarova KZ, Boyko OV, et al. Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104Week Results. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(2):52-9. doi: 10.17116/jnevro202312302152 (In Russ.)].